The Cancer and Leukemia Group B (CALGB) Statistical Center located at Duke University has primary responsibility for all statistical, data management, computing, and related activities for the CALGB. Faculty and staff statisticians collaborate closely with study chairs, committee chairs, and other investigators on the design, conduct, analysis, and reporting of all clinical trails and other studies conducted by the CALGB. The Data Management Center (DMC) is part of the Statistical Center and has the central responsibility of data quality control and database administration. All clinical data forms are sent to the DMC for editing, verification, and entry into the central official CALGB database system. Much of the scientific laboratory data is transmitted to the official database in an automated fashion. In addition to the scientific data, the database system also includes the administrative data necessary for managing the CALGB so that a single integrated database is used for all reports and analyses.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA033601-23
Application #
6512425
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1982-12-01
Project End
2003-03-31
Budget Start
2002-04-01
Budget End
2003-03-31
Support Year
23
Fiscal Year
2002
Total Cost
$4,962,283
Indirect Cost
Name
Duke University
Department
Public Health & Prev Medicine
Type
Schools of Medicine
DUNS #
071723621
City
Durham
State
NC
Country
United States
Zip Code
27705
McCleary, Nadine J; Hubbard, Joleen; Mahoney, Michelle R et al. (2018) Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance). J Geriatr Oncol 9:24-31
Innocenti, Federico; Jiang, Chen; Sibley, Alexander B et al. (2018) Genetic variation determines VEGF-A plasma levels in cancer patients. Sci Rep 8:16332
Parsons, J Kellogg; Pierce, John P; Mohler, James et al. (2018) Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer. BJU Int 121:534-539
Le-Petross, Huong T; McCall, Linda M; Hunt, Kelly K et al. (2018) Axillary Ultrasound Identifies Residual Nodal Disease After Chemotherapy: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance). AJR Am J Roentgenol 210:669-676
Sinicrope, Frank A; Shi, Qian; Allegra, Carmen J et al. (2017) Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials. JAMA Oncol 3:472-480
Baggstrom, Maria Q; Socinski, Mark A; Wang, Xiaofei F et al. (2017) Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance). J Thorac Oncol 12:843-849
Stock, W; Diouf, B; Crews, K R et al. (2017) An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine-Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia. Clin Pharmacol Ther 101:391-395
Fuchs, Charles S; Niedzwiecki, Donna; Mamon, Harvey J et al. (2017) Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). J Clin Oncol 35:3671-3677
Uy, Geoffrey L; Mandrekar, Sumithra J; Laumann, Kristina et al. (2017) A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv 1:331-340
Wang, Xiaofei; Wang, Xiaoyi; Hodgson, Lydia et al. (2017) Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials. Oncologist 22:189-198

Showing the most recent 10 out of 534 publications